Literature DB >> 28207639

Predictors of Waitlist Mortality in Portopulmonary Hypertension.

Michael J Krowka1, Richard N Channick2, Hilary M DuBrock2, David S Goldberg3, Norman L Sussman4, Sonja D Bartolome5, Zakiyah Kadry6, Reena J Salgia7, David C Mulligan8, Walter K Kremers9, Steven M Kawut3.   

Abstract

BACKGROUND: The current Organ Procurement Transplantation Network policy grants Model for End-Stage Liver Disease (MELD) exception points to patients with portopulmonary hypertension (POPH), but potentially important factors, such as severity of liver disease and pulmonary hypertension, are not included in the exception score, and may affect survival. The purpose of this study was to identify significant predictors of waitlist mortality in patients with POPH.
METHODS: We performed a retrospective cohort study of patients in the Organ Procurement and Transplantation Network database with hemodynamics consistent with POPH (defined as mean pulmonary arterial pressure >25 mm Hg and pulmonary vascular resistance [PVR] ≥240 dynes·s·cm) who were approved for a POPH MELD exception between 2006 and 2014. Using a Cox proportional hazards model, we identified predictors of waitlist mortality (or removal for clinical deterioration).
RESULTS: One hundred ninety adults were included. Age (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.00-1.08; P = 0.0499), initial native MELD score (HR, 1.11; 95% CI, 1.05-1.17; P < 0.001), and initial PVR (HR, 1.12 per 100 dynes·s·cm; 95% CI, 1.02-1.23; P = 0.02) were the only significant univariate predictors of waitlist mortality and remained significant predictors in a multivariate model, which had a c-statistic of 0.71. PVR and mean pulmonary arterial pressure were not significant predictors of posttransplant mortality.
CONCLUSIONS: Both the severity of liver disease and POPH (as assessed by MELD and PVR, respectively) were significantly associated with waitlist, but not posttransplant, mortality in patients with approved MELD exceptions for POPH. Both factors should potentially be included in the POPH MELD exception score to more accurately reflect waitlist mortality risk.

Entities:  

Mesh:

Year:  2017        PMID: 28207639      PMCID: PMC5481480          DOI: 10.1097/TP.0000000000001666

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  25 in total

1.  A spectrum of pulmonary vascular pathology in portopulmonary hypertension.

Authors:  M J Krowka; W D Edwards
Journal:  Liver Transpl       Date:  2000-03       Impact factor: 5.799

2.  MELD and PELD: application of survival models to liver allocation.

Authors:  R H Wiesner; S V McDiarmid; P S Kamath; E B Edwards; M Malinchoc; W K Kremers; R A Krom; W R Kim
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

3.  Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study.

Authors:  Isabelle O Colle; Richard Moreau; Erica Godinho; Jacques Belghiti; Florence Ettori; Alain Cohen-Solal; Hervé Mal; Jacques Bernuau; Jean Marty; Didier Lebrec; Dominique Valla; François Durand
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

4.  Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.

Authors:  David Goldberg; Benjamin French; Arwin Thomasson; K Rajender Reddy; Scott D Halpern
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

Review 5.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

6.  Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series.

Authors:  N Sussman; V Kaza; N Barshes; R Stribling; J Goss; C O'Mahony; E Zhang; J Vierling; A Frost
Journal:  Am J Transplant       Date:  2006-06-22       Impact factor: 8.086

Review 7.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

8.  Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates.

Authors:  M Torregrosa; J Genesca; A Gonzalez; A Evangelista; A Mora; C Margarit; R Esteban; J Guardia
Journal:  Transplantation       Date:  2001-02-27       Impact factor: 4.939

9.  MELD exceptions for portopulmonary hypertension: current policy and future implementation.

Authors:  D S Goldberg; S Batra; S Sahay; S M Kawut; M B Fallon
Journal:  Am J Transplant       Date:  2014-07-01       Impact factor: 8.086

10.  Portopulmonary hypertension: a report from the US-based REVEAL Registry.

Authors:  Michael J Krowka; Dave P Miller; Robyn J Barst; Darren Taichman; Raed A Dweik; David B Badesch; Michael D McGoon
Journal:  Chest       Date:  2011-07-21       Impact factor: 9.410

View more
  12 in total

Review 1.  Treatment Barriers in Portopulmonary Hypertension.

Authors:  Batool AbuHalimeh; Michael J Krowka; Adriano R Tonelli
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

Review 2.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease.

Authors:  Michael J Krowka
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

3.  Living donor liver transplantation versus donation after brain death and donation after circulatory death liver transplantation in the US.

Authors:  Matthew Black; Amar Gupta; Sumeet K Asrani; Tsung-Wei Ma; Giuliano Testa; Anji Wall
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-03-09

4.  Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension.

Authors:  Arun Jose; Shimul A Shah; Nadeem Anwar; Courtney R Jones; Kenneth E Sherman; Jean M Elwing
Journal:  Liver Transpl       Date:  2021-06-29       Impact factor: 6.112

5.  The impact of right ventricular pressure and function on survival in patients with pulmonary vein stenosis.

Authors:  Michelle C Sykes; Christina Ireland; Julia E McSweeney; Emily Rosenholm; Kristofer G Andren; Thomas J Kulik
Journal:  Pulm Circ       Date:  2018-04-30       Impact factor: 3.017

6.  Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes.

Authors:  Hilary M DuBrock; Reena J Salgia; Norman L Sussman; Sonja D Bartolome; Zakiyah Kadry; David C Mulligan; Sarah Jenkins; Kandace Lackore; Richard N Channick; Steven M Kawut; Michael J Krowka
Journal:  Transplant Direct       Date:  2019-05-22

Review 7.  Pulmonary manifestations of chronic liver disease: a comprehensive review.

Authors:  Stergios Soulaidopoulos; Ioannis Goulis; Evangelos Cholongitas
Journal:  Ann Gastroenterol       Date:  2020-03-27

8.  Causes and Circumstances of Death in Portopulmonary Hypertension.

Authors:  Sandeep Sahay; Sami Al Abdi; Celia Melillo; Jennie Newman; Raed A Dweik; Gustavo A Heresi; Adriano R Tonelli
Journal:  Transplant Direct       Date:  2021-06-08

9.  Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis.

Authors:  Michael Krowka; Emmanuelle Cottreel; Marius M Hoeper; Nick H Kim; Nicolas Martin; Olivier Sitbon; Jaume Bosch
Journal:  Liver Transpl       Date:  2020-04-30       Impact factor: 5.799

10.  Sex Differences in Portopulmonary Hypertension.

Authors:  Hilary M DuBrock; Rodrigo Cartin-Ceba; Richard N Channick; Steven M Kawut; Michael J Krowka
Journal:  Chest       Date:  2020-08-13       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.